Guidance Helps Sponsors Predict Developmental, Reproductive Effects
A new FDA guidance suggests a process sponsors can use to estimate developmental or reproductive risks associated with a new drug when there is a nonclinical toxicity finding but no definitive human data.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.